Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Aging and longevity biology in 2026: a crash course

    Aging biology studies why bodies decline with age and whether that decline can be slowed, since age is the main risk factor for cancer, heart disease, diabetes and dementia.[1][2] As of October 2026 several approaches extend lifespan in mice, and the first partial reprogramming therapy is in a human trial, but the FDA does not recognize aging as a disease and the strongest human evidence is still early.[3][4][5]

    Editor reviewedStrict sourcingUpdated Aging and longevity biologyLife sciencesHealth and medicine

    Why aging biology matters

    Getting older is the biggest single risk factor for most serious illnesses, including cancer, diabetes, heart disease and dementia.[1] Doctors usually treat these one at a time. Aging researchers ask a different question: what if you could slow the underlying process that makes all of them more likely?

    That idea is called the geroscience hypothesis. It says that slowing the molecular changes of aging could delay several chronic diseases at once and extend the number of years people live in good health.[2] In laboratory animals, aging can already be delayed with changes to genes, diet and drugs.[6] Whether that works in people is the open question this crash course follows.

    The field’s central premise is that aging is a shared upstream driver of most chronic morbidity and mortality, so intervening on it should compress multiple diseases at once.[1][2] Its scientific credibility dates to the late 1980s, when single-gene variants were found to extend lifespan in model organisms, and to the finding that the rate of aging is governed partly by evolutionarily conserved pathways.[7][8] A conclusive human test, however, would need long trials with hard endpoints such as disease incidence and death.[9]

    The map of the field

    The field has a few big branches:

    A useful map follows the 2023 hallmarks framework, which grew from nine hallmarks in 2013 to twelve by adding disabled macroautophagy, chronic inflammation and dysbiosis.[12][10] Each hallmark has to show up with age, speed aging when accentuated, and respond to intervention.[13] Translational work clusters around three intervention classes (senolytics, mTOR inhibition, partial-reprogramming) and a biomarker programme meant to supply surrogate endpoints.[14]

    Key ideas and evidence

    The strongest evidence still comes from animals. In 2009, rapamycin became the first drug shown to extend lifespan in both male and female mammals, even when started late in life.[3] The US National Institute on Aging’s interventions-testing-program has tested 54 agents in more than 30,000 mice since 2004, and most of the compounds that worked did so mainly in males.[15][16] Removing senescent cells delayed age-related problems in mice, and partial reprogramming restored vision in old mice.[17][18]

    Human evidence is thinner and mixed. A randomized trial of the senolytic combination dasatinib plus quercetin in 60 postmenopausal women missed its primary bone endpoint.[19] In the PEARL trial, low-dose rapamycin in healthy adults had adverse event rates similar to placebo, but its primary outcome did not change.[20] Caloric restriction in the CALERIE trial slowed one epigenetic measure of aging pace, with small effects.[21]

    Who the main players are

    Public funders and academic groups run much of the basic science, including the NIA’s mouse-testing programme.[22] Large private companies include altos-labs, which launched in 2022 with US$3 billion, and calico-life-sciences, announced by Google in 2013.[23][24] Smaller companies are taking the first products into trials: Life Biosciences with the eye therapy er-100, and Loyal with a dog lifespan drug, loy-002.[25][26]

    Funding is split between public programmes (NIA’s ITP), non-profits such as AFAR, which backs the tame-trial of metformin, and well-capitalised private companies.[22][27] Altos Labs ($3B at launch, institutes in the Bay Area, San Diego and Cambridge, UK) focuses on cell rejuvenation. Calico has a long-running AbbVie collaboration on aging and age-related disease, extended in 2018 and 2021.[23][28][29] Both companies also invest heavily in computation and machine learning.[30][31] Prize money is another lever: XPRIZE Healthspan is a US$101 million competition to restore muscle, cognitive and immune function by at least 10 years.[32]

    Where the frontier is in October 2026

    • Reprogramming reaches people. The FDA cleared the first partial reprogramming trial in January 2026. Dosing began in June, and on 8 October Life Biosciences reported no serious adverse events in its first three patients.[25][4][33]
    • A lifespan drug for dogs nears a decision. Loyal’s LOY-002 has cleared two of three major FDA requirements for conditional approval. Manufacturing review remains.[34]
    • Better clocks, not yet validated. New multimodal and protein-based clocks appeared in 2026, but experts still lack agreed validation standards.[35][14]
    • Competitions move to trials. XPRIZE named 20 Healthspan finalists in August 2026.[36]
    • More dog drugs, fewer senolytic companies. Loyal says a third dog drug, LOY-003 for large breeds, cleared the FDA’s effectiveness step in September 2026.[37] The senolytic developer Unity Biotechnology dissolved in 2025.[38]
    • AI enters protein design for rejuvenation. OpenAI and Retro Biosciences reported early, unreviewed results from an AI model that redesigned two Yamanaka factors; see openai.[39]

    The field also disagrees with itself. A 2024 survey of aging researchers found no majority view on what aging is or what rejuvenation means.[40] The debates are covered in the aging-as-a-disease debate, and the latest milestones in the longevity tracker.

    Nothing on this page is medical advice. Most interventions described here are experimental.

    Questions readers ask

    Is there a drug approved to slow human aging?

    No. The FDA does not recognize aging as a disease and no regulatory framework exists for approving aging-targeted therapies, so they are tested against specific diseases instead.[5]

    What are the hallmarks of aging?

    A widely cited 2023 review lists twelve, including genomic instability, telomere attrition, epigenetic alterations, cellular senescence, mitochondrial dysfunction, chronic inflammation and dysbiosis.[10]

    Does rapamycin extend lifespan?

    In mice, yes. A 2009 study found it extended lifespan in both sexes even when started late in life. A 48-week trial in healthy people reported similar adverse events to placebo but no change in its primary outcome.[3][20]

    Has age reversal been tested in humans?

    Partial reprogramming entered its first human trial in 2026. Life Biosciences' ER-100 is being tested for safety in eye diseases, and early data from three patients showed no serious adverse events.[4][33]

    Are epigenetic age tests reliable?

    They are improving but imperfect. Technical noise can shift some clocks by up to 9 years between repeat measurements, and experts have not yet agreed how to validate them for clinical use.[41][14]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      Age-related loss of physiological integrity is the primary risk factor for major human diseases including cancer, diabetes, cardiovascular disorders and neurodegenerative diseases. confirmedas of 2013-06-06

    2. [2]

      The geroscience hypothesis proposes that therapies slowing or reversing molecular changes of aging could delay or prevent multiple chronic diseases at once and extend healthy lifespan. confirmedas of 2023-02-09

    3. [3]

      In 2009 rapamycin, an inhibitor of the mTOR pathway, extended median and maximal lifespan in both male and female mice when feeding began at 600 days of age, the first drug shown to extend lifespan in both sexes of a mammal. confirmedas of 2009-07-08

    4. [4]

      On 9 June 2026 Life Biosciences announced the first patient dosed in its Phase 1 trial of ER-100 (NCT07290244) in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), which evaluates safety and tolerability with additional visual-function endpoints. confirmedas of 2026-06-09

    5. [5]

      Papers published in 2025 in peer-reviewed journals state that the FDA does not recognize aging as a disease and that no regulatory framework exists for developing or approving therapies that target aging, so such therapies are developed through disease-specific pipelines. confirmedas of 2025-08-04

    6. [6]

      Aging in mammals can be delayed in the laboratory with genetic, dietary and drug-based approaches. confirmedas of 2014-11-06

    7. [7]

      Aging biology gained scientific credibility around 1989 with the discovery of gene variants that extend the lifespan of multicellular model organisms. confirmedas of 2019-07-10

    8. [8]

      The rate of aging is controlled, at least in part, by genetic pathways and biochemical processes that are conserved in evolution. confirmedas of 2013-06-06

    9. [9]

      Researchers note that a conclusive test of the geroscience hypothesis requires long trials measuring hard endpoints such as chronic disease incidence and mortality. confirmedas of 2023-02-09

    10. [10]

      A 2023 update in Cell expanded the list to twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation and dysbiosis. confirmedas of 2026-10-10

    11. [11]

      In 2013 a multi-tissue DNA methylation age predictor was built from about 8,000 samples in 82 datasets covering 51 healthy tissues and cell types. confirmedas of 2026-10-10

    12. [12]

      A 2013 review in Cell proposed nine tentative hallmarks of aging as common denominators across organisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communication. confirmedas of 2013-06-06

    13. [13]

      In the 2023 framework a process counts as a hallmark if it shows up with age, if accentuating it experimentally speeds aging, and if intervening on it can slow, stop or reverse aging. confirmedas of 2026-10-10

    14. [14]

      Aging biomarkers could serve as surrogate endpoints for trials of longevity interventions, but as of 2024 there was no consensus on how they should be validated before clinical use. confirmedas of 2024-02-14

    15. [15]

      Over two decades the ITP has tested 54 agents in more than 30,000 mice. confirmedas of 2025-07-24

    16. [16]

      Most compounds that extended lifespan in the ITP worked primarily or only in male mice. confirmedas of 2025-07-24

    17. [17]

      In a 2011 study in progeroid (prematurely aging) mice, genetically removing p16Ink4a-positive senescent cells delayed age-related problems in fat, muscle and eye, and late-life clearance slowed disorders that had already set in. confirmedas of 2011-11-02

    18. [18]

      In 2020, expressing three factors (Oct4, Sox2 and Klf4, or OSK) in mouse retinal ganglion cells restored youthful DNA methylation patterns, promoted nerve regeneration and reversed vision loss in a glaucoma model and in aged mice. confirmedas of 2020-12-02

    19. [19]

      In a 2024 phase 2 randomized trial in 60 postmenopausal women, intermittent dasatinib plus quercetin did not change the primary bone-resorption marker at 20 weeks compared with control. confirmedas of 2024-07-02

    20. [20]

      In PEARL, adverse events were similar across groups and the primary outcome, visceral fat, did not change significantly; some secondary measures improved, such as lean tissue mass and pain in women on 10 mg. confirmedas of 2025-04-04

    21. [21]

      In a post hoc analysis of CALERIE, caloric restriction slowed DunedinPACE but did not significantly change biological age estimates from other clocks including PhenoAge and GrimAge, and effect sizes were small. confirmedas of 2023-02-09

    22. [22]

      The US National Institute on Aging launched the Interventions Testing Program (ITP) in 2004 as a multi-site effort testing candidate compounds in genetically heterogeneous UM-HET3 mice. confirmedas of 2025-07-24

    23. [23]

      Altos Labs launched on 19 January 2022 with US$3 billion in committed funding, initially based in the San Francisco Bay Area, San Diego and Cambridge, UK. confirmedas of 2022-01-19

    24. [24]

      Google announced Calico in September 2013, and Arthur Levinson is its founder and CEO. confirmedas of 2026-10-10

    25. [25]

      On 28 January 2026 Life Biosciences announced FDA clearance of its investigational new drug (IND) application for ER-100 in optic neuropathies, the first partial epigenetic reprogramming therapy cleared for human testing. confirmedas of 2026-01-28

    26. [26]

      In February 2025 the FDA's Center for Veterinary Medicine accepted the reasonable expectation of effectiveness (RXE) section for Loyal's LOY-002, a daily pill intended to extend lifespan in senior dogs. confirmedas of 2025-02-26

    27. [27]

      The American Federation for Aging Research (AFAR) has supported the TAME initiative. confirmedas of 2016-06-14

    28. [28]

      In September 2014 AbbVie and Calico announced a research collaboration on aging and age-related diseases, each committing an initial US$250 million with up to US$1.5 billion in total. confirmedas of 2014-09-03

    29. [29]

      AbbVie and Calico extended their 2014 collaboration in 2018 and again in July 2021; by then it had advanced three clinical-stage programs in immuno-oncology and neurodegeneration and had more than 20 early-stage programs. confirmedas of 2021-07-27

    30. [30]

      Altos Labs formed an Institute of Computation to build computational models of biological resilience at the cell, organ and organism levels, alongside its Institutes of Science and Institute of Medicine. confirmedas of 2026-10-10

    31. [31]

      Calico says it combines Alphabet's computing with large human genetic, phenotypic, clinical and lifestyle datasets, feeding machine learning used for target discovery and molecular design. confirmedas of 2026-06-22

    32. [32]

      XPRIZE Healthspan is a US$101 million competition, launched in 2023 and running to 2030, challenging teams to restore muscle, cognitive and immune function by at least 10 years, with a goal of 20. confirmedas of 2026-10-10

    33. [33]

      In first-in-human data released on 8 October 2026, three open-angle glaucoma participants given the lowest ER-100 dose had no dose-limiting toxicities or serious adverse events. confirmedas of 2026-10-08

    34. [34]

      The manufacturing section must still be accepted before LOY-002 can be considered for conditional approval; as of October 2026 Loyal says two of three major requirements are complete and approval is not guaranteed. confirmedas of 2026-10-10

    35. [35]

      A 2026 Cell study built clinical, multimodal and organ-level aging clocks from a cohort of 2,019 Chinese adults aged 18 to 91 and reported that plasma protein clocks serve as efficient proxies for systemic physiological capacity. confirmedas of 2026-05-08

    36. [36]

      On 11 August 2026 XPRIZE named 20 Healthspan finalist teams, 10 of which received US$1 million milestone awards. confirmedas of 2026-08-11

    37. [37]

      On 16 September 2026 Loyal said the FDA had accepted the reasonable expectation of effectiveness (RXE) for LOY-003, a once-daily tablet meant to extend the lifespan of large and giant-breed dogs by lowering growth hormone and IGF-1; Loyal says this is its third RXE, after LOY-001 and LOY-002. reportedas of 2026-09-16

    38. [38]

      Unity Biotechnology, the developer of the senolytic UBX1325, cut all of its staff in May 2025 after 36-week data from its ASPIRE study, and its stockholders approved the company's liquidation and dissolution on 18 September 2025. confirmedas of 2025-09-19

    39. [39]

      In January 2025 OpenAI said a protein-engineering model, GPT-4b micro, built with the longevity company Retro Biosciences, suggested changes that made two Yamanaka factors more than 50 times as effective on some preliminary measures; outside scientists could not assess the claim until it was published. reportedas of 2025-01-17

    40. [40]

      A 2024 survey of aging researchers found no consensus, and not even a majority view, on core questions such as what aging is, what causes it, when it begins and what counts as rejuvenation. confirmedas of 2024-12-03

    41. [41]

      Technical noise in DNA methylation data can make six prominent epigenetic clocks disagree by up to 9 years between replicate measurements of the same sample. confirmedas of 2022-07-15

    Revision history (2)
    1. Page created.
    2. Refresh: added LOY-003, Unity Biotechnology's dissolution, OpenAI and Retro Biosciences' AI-designed factors, and the companies' computation investments.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Aging and longevity biology in 2026: a crash course." ContentLora, updated Oct 10, 2026. https://contentlora.com/explain/longevity

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents